Time-to-Statin Prescription for Primary Atherosclerotic Cardiovascular Disease Prevention in a Lung Cancer Screening Program in Missouri: A Retrospective Cohort Study
- 1Washington University in St Louis Department of Surgery
Abstract
BackgroundIndividuals undergoing lung cancer screening (LCS) represent a population at high risk for atherosclerotic cardiovascular disease (ASCVD), yet opportunities for cardiovascular prevention during screening encounters may be underutilized. While prior studies have examined whether statins are prescribed in eligible patients, little is known about the timing of statin initiation following LCS, particularly among statin-naive individuals.
MethodsWe conducted a retrospective cohort study using electronic health record data from a large academic health system in Missouri. Adults aged 50-80 who underwent LCS between January 1, 2015, and December 31, 2023, were statin-naive, and met 2019 ACC/AHA criteria for primary prevention were included. The primary outcome was time-to-statin initiation following LCS. Kaplan-Meier methods and Cox proportional hazards models were used to evaluate timing and predictors of statin initiation across demographic, clinical, and socioeconomic subgroups.
ResultsAmong 3,100 statin-eligible, statin-naive individuals who had undergone LCS, only 27.3% were prescribed a statin within one year of LCS. Uptake accrued gradually (10.5% by 90 days; 17.8% by 180 days; 23.2% by 270 days; 27.1% by 360 days). In adjusted models, earlier statin initiation was independently associated with a higher ASCVD risk category, a cardiology visit in the year preceding LCS, and former (versus current) smoking; older age and male sex were associated with slower initiation. Race, insurance type, and area deprivation were not independently associated with time-to-statin initiation.
ConclusionsDespite high ASCVD risk, most statin-eligible patients undergoing LCS did not receive timely statin therapy. Earlier initiation tracked calculated ASCVD risk and specialty (cardiology) contact rather than race, sex, insurance, or area deprivation. Because most patients at high calculated risk still went untreated, integrating cardiovascular risk assessment and preventive decision support into LCS workflows may help reduce missed opportunities for ASCVD prevention.
Related
- Trends and Factors Associated with LDL-C Treatment Target Attainment Rates among Patients with Secondary Prevention Setting of Atherosclerotic Cardiovascular Disease: Assessments from Japanese Health Checkup Data
- Bringing Cardiovascular Prevention into the Community: Protocol for an Observational Study of a Mosque-Based Health Initiative Combining Education and Cardiovascular Screening
- Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study
- Cardiac screening in the young for the detection of cardiovascular disease and prevention of sudden cardiac death
- Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial
BibTeX
@misc{ngang2026timetostatin,
title = {{Time-to-Statin Prescription for Primary Atherosclerotic Cardiovascular Disease Prevention in a Lung Cancer Screening Program in Missouri: A Retrospective Cohort Study}},
author = {I. Che Ngang and E. K. Zewde and S. Gopalsamy Ramaswamy and A. Anandarajah and B. Bowe and B. Odeny},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.16.26363270},
url = {https://www.medrxiv.org/content/10.64898/2026.09.16.26363270v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Time-to-Statin Prescription for Primary Atherosclerotic Cardiovascular Disease Prevention in a Lung Cancer Screening Program in Missouri: A Retrospective Cohort Study
AU - I. Che Ngang
AU - E. K. Zewde
AU - S. Gopalsamy Ramaswamy
AU - A. Anandarajah
AU - B. Bowe
AU - B. Odeny
PY - 2026
DA - 2026/09/16
PB - medRxiv
DO - 10.64898/2026.09.16.26363270
UR - https://www.medrxiv.org/content/10.64898/2026.09.16.26363270v1
AB - BackgroundIndividuals undergoing lung cancer screening (LCS) represent a population at high risk for atherosclerotic cardiovascular disease (ASCVD), yet opportunities for cardiovascular prevention during screening encounters may be underutilized. While prior studies have examined whether statins are prescribed in eligible patients, little is known about the timing of statin initiation following LCS, particularly among statin-naive individuals. MethodsWe conducted a retrospective cohort study using electronic health record data from a large academic health system in Missouri. Adults aged 50-80 who underwent LCS between January 1, 2015, and December 31, 2023, were statin-naive, and met 2019 ACC/AHA criteria for primary prevention were included. The primary outcome was time-to-statin initiation following LCS. Kaplan-Meier methods and Cox proportional hazards models were used to evaluate timing and predictors of statin initiation across demographic, clinical, and socioeconomic subgroups. ResultsAmong 3,100 statin-eligible, statin-naive individuals who had undergone LCS, only 27.3% were prescribed a statin within one year of LCS. Uptake accrued gradually (10.5% by 90 days; 17.8% by 180 days; 23.2% by 270 days; 27.1% by 360 days). In adjusted models, earlier statin initiation was independently associated with a higher ASCVD risk category, a cardiology visit in the year preceding LCS, and former (versus current) smoking; older age and male sex were associated with slower initiation. Race, insurance type, and area deprivation were not independently associated with time-to-statin initiation. ConclusionsDespite high ASCVD risk, most statin-eligible patients undergoing LCS did not receive timely statin therapy. Earlier initiation tracked calculated ASCVD risk and specialty (cardiology) contact rather than race, sex, insurance, or area deprivation. Because most patients at high calculated risk still went untreated, integrating cardiovascular risk assessment and preventive decision support into LCS workflows may help reduce missed opportunities for ASCVD prevention.
ER -